Second Genome is developing microbiome-modulating precision therapies that address significant unmet need in disease and wellness. We utilize a proprietary discovery platform to unravel the complexity of the human microbiome and to drive advances in nutritional and pharmaceutical therapies. We also work with our global collaborators to identify novel biomarkers for classifying patient populations and to assess the impact of novel microbiome-modulating products.